Alx Oncology Holdings (ALXO) Cash from Financing Activities (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Cash from Financing Activities of $139.6 million for Q1 2026, up 20489.23% sequentially from $678000.0 in Q4 2025, and up 214661.54% YoY from N/an in Q1 2025.
Powered by 
Analysis
Alx Oncology Holdings (ALXO) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Cash from Financing Activities for 8 years, with the latest figure at $139.6 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 214661.54% year-over-year to $139.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $139.9 million (up 403.28% YoY) and the FY2025 annual result came in at $362000.0, down 98.83% from the prior year.
- Cash from Financing Activities advanced to $139.6 million in Q1 2026 per ALXO's latest filing, from $678000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $139.6 million in Q1 2026 and troughed at -$222000.0 in Q2 2025.
- A 5-year average of $14.1 million and a median of $328000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 233.75% in 2023, then surged 214661.54% in 2026.
- Over 5 years, Cash from Financing Activities stood at $9.5 million in 2022, then soared by 523.19% to $59.2 million in 2023, then sank by 99.45% to $328000.0 in 2024, then soared by 106.71% to $678000.0 in 2025, then jumped by 20489.23% to $139.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $139.6 million, $678000.0, and -$159000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Alx Oncology Holdings | 273.99 Mn | 273.99 Mn | - | 137,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 137,000.00 |
| Mar 31, 2026 | 139.60 Mn |
| Dec 31, 2025 | 678,000.00 |
| Sep 30, 2025 | -159,000.00 |
| Jun 30, 2025 | -222,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Dec 31, 2024 | 328,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Jun 30, 2024 | 27.15 Mn |
| Mar 31, 2024 | 3.09 Mn |
| Dec 31, 2023 | 59.17 Mn |
| Sep 30, 2023 | -111,000.00 |
| Jun 30, 2023 | 343,000.00 |
| Mar 31, 2023 | -107,000.00 |
| Dec 31, 2022 | 9.49 Mn |
| Sep 30, 2022 | -136,000.00 |
| Jun 30, 2022 | 422,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Dec 31, 2021 | 524,000.00 |
| Sep 30, 2021 | 439,000.00 |